ASTELLAS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,506 JPY | +3.51% |
|
+2.76% | -10.68% |
| Apr. 25 | Astellas Pharma Inc. Announces Board and Committee Retirements | CI |
| Apr. 25 | European Commission Approves Astellas Pharma Label Extension for Xtandi | MT |
Presenter SpeechHiromitsu Ikeda (Executives)[Interpreted] Thank you very much for your partici...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,506
JPY
Average target price
2,025
JPY
Spread / Average Target
+34.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.68% | 16.77B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B |
- Stock Market
- Equities
- 4503 Stock
- News Astellas Pharma Inc.
- Transcript : Astellas Pharma Inc., 2022 Earnings Call, Apr 27, 2022
